Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s leukemia drug gets conditional European approval

[Reuters] – European health regulators on Friday conditionally approved Amgen Inc’s rare blood cancer drug, Blincyto, which is one of the world’s most expensive cancer treatments. The U.S. Food and Drug Administration in . . . → Read More: Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s leukemia drug gets conditional European approval Similar Articles: Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen wins first approval for new class of cholesterol drugs Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Positive BLINCYTO® (blinatumomab) Phase 2 Study Results In Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia Market Update: Amgen Inc (NASDAQ:AMGN) – FDA panel recommends approval for Amgen’s skin cancer immunotherapy